about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Biotech part­ner drops Glax­o­SmithK­line’s ad­ju­vant as it moves Covid-19 vac­cine in­to PhII/III, cit­ing ...

5 years ago
Deals
Coronavirus

Cataba­sis Phar­ma­ceu­ti­cals snaps up HAE an­ti­body in buy­out; Glad­stone, UCSF sci­en­tist spear­head launch of neu­ro ...

5 years ago
News Briefing

Covid-19 roundup: As­traZeneca gets EMA thumbs up for vac­cine amid bit­ter feud with EU; No­var­tis jumps in to ...

5 years ago
Coronavirus

Ad­vo­ca­cy groups don't want Janet Wood­cock to head the FDA, blast­ing ‘reg­u­la­to­ry fail­ures’ in opi­oid cri­sis

5 years ago
People
FDA+

Covid-19 roundup: Con­tro­ver­sy around colchicine per­co­lates af­ter study fail­ure; As­traZeneca's meet­ing with EU was ...

5 years ago
Coronavirus

BeiGene's PD-1 scores PhI­II win in esophageal can­cer — a 'key in­di­ca­tion' tapped by No­var­tis in $650M deal

5 years ago
R&D

Leaps by Bay­er backs a pro­tein en­gi­neer­ing start­up tak­ing on Aim­mune — and Nestlé — in peanut al­ler­gy

5 years ago
Financing
Startups

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

5 years ago
Coronavirus

As tar­get­ed ther­a­pies get ever more pre­cise, Deer­field un­veils $50M bet on a Har­vard pro­fes­sor's chem­istry in­sights

5 years ago
Financing
Startups

My­ovant beefs up da­ta pack­age in NDA #3, boost­ing its case for longterm dos­ing of Pfiz­er-part­nered re­l­u­golix

5 years ago
R&D

Covid-19 roundup: As­traZeneca, Pfiz­er come un­der fire for pro­duc­tion de­lays; Mod­er­na con­sid­ers third boost­er dose to ...

5 years ago
Coronavirus

Can strug­gling Iterum turn the cor­ner to an an­tibi­ot­ic suc­cess sto­ry? They will know in six months

5 years ago
FDA+

Roche amps up its bis­pe­cif­ic at­tack on Eylea with more PhI­II da­ta — but just how threat­en­ing is it?

5 years ago
R&D

Fast on Glax­o­SmithK­line's heels, Au­rinia wins OK to steer a sec­ond lu­pus nephri­tis drug straight to the mar­ket

5 years ago
R&D

In­cyte's PD-1 pri­or­i­ty re­view draws mut­ed cheer — but an­a­lysts say it's all about get­ting a foot in the door

5 years ago
FDA+

Eli Lil­ly's an­ti­body cuts risk of Covid-19 by up to 80% among the most vul­ner­a­ble — but will it have a place next ...

5 years ago
R&D
Coronavirus

End­points poll: Janet Wood­cock takes the (in­ter­im) helm at the FDA. And a large ma­jor­i­ty of our read­ers want her to ...

5 years ago
People
FDA+

Covid-19 roundup: BioN­Tech of­fers da­ta show­ing Pfiz­er-part­nered vac­cine pro­tects against vari­ant; No­vavax at­trib­ut­es ...

5 years ago
Coronavirus

As he wraps stormy FDA tenure, Hahn ad­mits 'there was a sub­stan­tial amount of pres­sure' from White House — re­port

5 years ago
People

News brief­ing: Beam bags a $260M pri­vate place­ment; mi­Ra­gen re­brands to Virid­i­an Ther­a­peu­tics

5 years ago
News Briefing

Ox­ford gets £100M to seize a 'break­through mo­men­t' in fight­ing su­per­bugs

5 years ago
Discovery

'Bluest of blue-chip in­vestors' pump $94M in­to Sekar Kathire­san's quest to bring CRISPR to the heart

5 years ago
Financing
Cell/Gene Tx

A car­dio­vas­cu­lar cell ther­a­py play­er grabs $54M for a new be­gin­ning — where next-gen CAR-T ap­proach fea­tures ...

5 years ago
Financing

Janet Wood­cock is in the run­ning for FDA com­mis­sion­er — what does that mean for the agen­cy's fu­ture?

5 years ago
People
FDA+
First page Previous page 57585960616263 Next page Last page
A service from the Financial Times